挺过风暴：应对新冠疫情 - Suppr

Surviving the storm: Dealing with COVID-19.

作者信息

Vandenbark Arthur A, Meza-Romero Roberto, Offner Halina

机构信息

Neuroimmunology Research, R&D-31, VA Portland Health Care System, 3710 SW U.S. Veterans Hospital Rd., Portland, OR 97239, USA; Department of Neurology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA; Department of Molecular Microbiology & Immunology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA.

出版信息

Cell Immunol. 2020 Aug;354:104153. doi: 10.1016/j.cellimm.2020.104153. Epub 2020 Jun 13.

DOI:10.1016/j.cellimm.2020.104153

PMID:32563849

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7293470/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/267b/7293470/84e2fb5a1a7f/gr1_lrg.jpg

相似文献

Surviving the storm: Dealing with COVID-19.

Cell Immunol. 2020 Aug;354:104153. doi: 10.1016/j.cellimm.2020.104153. Epub 2020 Jun 13.

The COVID-19 Cytokine Storm; What We Know So Far.

Front Immunol. 2020 Jun 16;11:1446. doi: 10.3389/fimmu.2020.01446. eCollection 2020.

Leukoerythroblastosis and plasmacytoid lymphocytes in a child with SARS-CoV-2-associated multisystem inflammatory syndrome.

Blood. 2020 Aug 13;136(7):914. doi: 10.1182/blood.2020007132.

Cytokine storm intervention in the early stages of COVID-19 pneumonia.

Cytokine Growth Factor Rev. 2020 Jun;53:38-42. doi: 10.1016/j.cytogfr.2020.04.002. Epub 2020 Apr 25.

Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm.

Med Hypotheses. 2020 Oct;143:109897. doi: 10.1016/j.mehy.2020.109897. Epub 2020 May 30.

SARS-CoV-2: An immunogenetics call to arms.

Int J Immunogenet. 2020 Aug;47(4):319-323. doi: 10.1111/iji.12504. Epub 2020 Jul 12.

After 62 years of regulating immunity, dexamethasone meets COVID-19.

Nat Rev Immunol. 2020 Oct;20(10):587-588. doi: 10.1038/s41577-020-00421-x.

Should we unstress SARS-CoV-2 infected cells?

Cytokine Growth Factor Rev. 2020 Aug;54:3-5. doi: 10.1016/j.cytogfr.2020.06.011. Epub 2020 Jun 11.

Acute inflammation and pathogenesis of SARS-CoV-2 infection: Cannabidiol as a potential anti-inflammatory treatment?

Cytokine Growth Factor Rev. 2020 Jun;53:63-65. doi: 10.1016/j.cytogfr.2020.05.008. Epub 2020 May 20.

Cytokine Release Syndrome in COVID-19 Patients, A New Scenario for an Old Concern: The Fragile Balance between Infections and Autoimmunity.

Int J Mol Sci. 2020 May 8;21(9):3330. doi: 10.3390/ijms21093330.

引用本文的文献

Proteomics research of SARS-CoV-2 and COVID-19 disease.

Med Rev (2021). 2022 Sep 14;2(4):427-445. doi: 10.1515/mr-2022-0016. eCollection 2022 Aug.

Proteomic investigation reveals dominant alterations of neutrophil degranulation and mRNA translation pathways in patients with COVID-19.

iScience. 2021 Mar 19;24(3):102135. doi: 10.1016/j.isci.2021.102135. Epub 2021 Feb 4.

SARS-CoV-2 Infection: Symptoms of the Nervous System and Implications for Therapy in Neurological Disorders.

Neurol Ther. 2021 Jun;10(1):31-42. doi: 10.1007/s40120-020-00225-0. Epub 2020 Nov 23.

本文引用的文献

Severe COVID-19: A Review of Recent Progress With a Look Toward the Future.

Front Public Health. 2020 May 13;8:189. doi: 10.3389/fpubh.2020.00189. eCollection 2020.

COVID-19: consider cytokine storm syndromes and immunosuppression.

Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.

A novel neurotherapeutic for multiple sclerosis, ischemic injury, methamphetamine addiction, and traumatic brain injury.

J Neuroinflammation. 2019 Jan 23;16(1):14. doi: 10.1186/s12974-018-1393-0.

Increased CD74 binding and EAE treatment efficacy of a modified DRα1 molecular construct.

Metab Brain Dis. 2019 Feb;34(1):153-164. doi: 10.1007/s11011-018-0331-2. Epub 2018 Oct 23.

MIF and D-DT are potential disease severity modifiers in male MS subjects.

Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):E8421-E8429. doi: 10.1073/pnas.1712288114. Epub 2017 Sep 18.

Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary disease.

Eur Respir J. 2014 Aug;44(2):475-82. doi: 10.1183/09031936.00003814. Epub 2014 Apr 2.

Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study.

Autoimmune Dis. 2012;2012:954739. doi: 10.1155/2012/954739. Epub 2012 Apr 5.

Characterization of human platelet binding of recombinant T cell receptor ligand.

J Neuroinflammation. 2010 Nov 8;7:75. doi: 10.1186/1742-2094-7-75.

A promising therapeutic approach for multiple sclerosis: recombinant T-cell receptor ligands modulate experimental autoimmune encephalomyelitis by reducing interleukin-17 production and inhibiting migration of encephalitogenic cells into the CNS.

J Neurosci. 2007 Nov 14;27(46):12531-9. doi: 10.1523/JNEUROSCI.3599-07.2007.

Recombinant HLA-DP2 binds beryllium and tolerizes beryllium-specific pathogenic CD4+ T cells.

J Immunol. 2006 Sep 15;177(6):3874-83. doi: 10.4049/jimmunol.177.6.3874.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Surviving the storm: Dealing with COVID-19.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献